Gallbladder Carcinoma Clinical Trial
Official title:
A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study. These information will be used to recommend target therapy which may be more likely to result in a beneficial response. Patients will receive target antitumor agents according to the result of genomic and proteomic profiling and be monitored by circulating tumor DNA(ctDNA). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05285358 -
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
|
Phase 1 | |
| Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04853017 -
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05222854 -
Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"
|
||
| Not yet recruiting |
NCT05681949 -
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
|
N/A | |
| Active, not recruiting |
NCT02151084 -
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
|
Phase 2 | |
| Terminated |
NCT01855724 -
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
|
Phase 2 | |
| Withdrawn |
NCT02105350 -
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
| Completed |
NCT02649712 -
Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction
|
N/A | |
| Recruiting |
NCT05194072 -
A Study of SGN-B7H4V in Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03581435 -
A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients
|
||
| Completed |
NCT03201458 -
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
|
Phase 2 | |
| Completed |
NCT04740164 -
A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP
|
N/A | |
| Completed |
NCT02333188 -
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
| Recruiting |
NCT05712356 -
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
| Recruiting |
NCT03702491 -
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04068194 -
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
|
Phase 1/Phase 2 |